Clinical Trial Results: Positive clinical trial data often leads to stock price increases, while negative data can cause significant drops.

Regulatory Approvals: FDA approval of TSHA's gene therapies would likely boost the stock price, while rejection or delays can negatively impact it.

Competition: Developments from competing gene therapy companies can affect investor sentiment towards TSHA and its stock price.

Market Conditions: Overall market trends, particularly in the biotechnology sector, can influence TSHA's stock price regardless of company-specific news.

Financial Performance: TSHA's cash runway, burn rate, and ability to secure funding impact investor confidence and stock valuation.

Partnerships and Collaborations: Strategic partnerships with other companies or research institutions can positively influence stock price.

Intellectual Property: The strength and scope of TSHA's patent portfolio affect its competitive advantage and attractiveness to investors.

Management Team: Investor confidence in the leadership team and their strategic decisions plays a crucial role in stock performance.

News and Media Coverage: Positive or negative news articles and media reports can sway investor sentiment and affect stock price.

Analyst Ratings and Price Targets: Analyst ratings and price targets can influence investor perceptions of the stock's potential value.